Features of anosmia in COVID-19.
Adult
Aged
Betacoronavirus
/ physiology
COVID-19
Cohort Studies
Comorbidity
Coronavirus Infections
/ complications
Female
France
/ epidemiology
Humans
Male
Middle Aged
Olfaction Disorders
/ epidemiology
Oxygen Inhalation Therapy
Pandemics
Pneumonia
/ epidemiology
Pneumonia, Viral
/ complications
Prevalence
Respiratory Function Tests
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
Time Factors
Anosmia
COVID-19
Dysgeusia
Journal
Medecine et maladies infectieuses
ISSN: 1769-6690
Titre abrégé: Med Mal Infect
Pays: France
ID NLM: 0311416
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
10
04
2020
accepted:
15
04
2020
pubmed:
20
4
2020
medline:
13
8
2020
entrez:
20
4
2020
Statut:
ppublish
Résumé
Medical publications about anosmia with COVID-19 are scarce. We aimed to describe the prevalence and features of anosmia in COVID-19 patients. We retrospectively included COVID-19 patients with anosmia between March 1st and March 17th, 2020. We used SARS-CoV-2 real time PCR in respiratory samples to confirm the cases. Fifty-four of 114 patients (47%) with confirmed COVID-19 reported anosmia. Mean age of the 54 patients was 47 (±16) years; 67% were females and 37% were hospitalised. The median Charlson comorbidity index was 0.70 (±1.6 [0-7]). Forty-six patients (85%) had dysgeusia and 28% presented with pneumonia. Anosmia began 4.4 (±1.9 [1-8]) days after infection onset. The mean duration of anosmia was 8.9 (±6.3 [1-21]) days and 98% of patients recovered within 28 days. Anosmia was present in half of our European COVID-19 patients and was often associated with dysgeusia.
Sections du résumé
BACKGROUND
BACKGROUND
Medical publications about anosmia with COVID-19 are scarce. We aimed to describe the prevalence and features of anosmia in COVID-19 patients.
METHODS
METHODS
We retrospectively included COVID-19 patients with anosmia between March 1st and March 17th, 2020. We used SARS-CoV-2 real time PCR in respiratory samples to confirm the cases.
RESULTS
RESULTS
Fifty-four of 114 patients (47%) with confirmed COVID-19 reported anosmia. Mean age of the 54 patients was 47 (±16) years; 67% were females and 37% were hospitalised. The median Charlson comorbidity index was 0.70 (±1.6 [0-7]). Forty-six patients (85%) had dysgeusia and 28% presented with pneumonia. Anosmia began 4.4 (±1.9 [1-8]) days after infection onset. The mean duration of anosmia was 8.9 (±6.3 [1-21]) days and 98% of patients recovered within 28 days.
CONCLUSIONS
CONCLUSIONS
Anosmia was present in half of our European COVID-19 patients and was often associated with dysgeusia.
Identifiants
pubmed: 32305563
pii: S0399-077X(20)30110-4
doi: 10.1016/j.medmal.2020.04.006
pmc: PMC7162775
pii:
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
436-439Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Acta Otolaryngol. 1995 Jan;115(1):88-92
pubmed: 7762392
Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):284-285
pubmed: 32253163
Rhinology. 2020 Jun 1;58(3):299-301
pubmed: 32240279
Laryngoscope. 2020 Jul;130(7):1787
pubmed: 32237238
Laryngoscope. 2007 Feb;117(2):272-7
pubmed: 17277621
Laryngoscope. 2020 Nov;130(11):2537-2543
pubmed: 32219846
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
Clin Infect Dis. 2020 Jul 28;71(15):706-712
pubmed: 32109279
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Am J Rhinol Allergy. 2014 Sep-Oct;28(5):419-22
pubmed: 25198029